Interim Phase III Data Show Praxbind® (idarucizumab) Reverses Dabigatran (Pradaxa®) in Emergency Situations

•  A single 5g dose of idarucizumab immediately reversed the anticoagulant effect of dabigatran in   all patients evaluated • Results based on analyses of high-risk patients from RE-VERSE AD™ study • Data presented today at ACC 2016 Scientific Session and Expo
Source: Boehringer Ingelheim Press Releases - Category: Research Source Type: news